Beckley Waves

Beckley Waves

Beckley Waves was co-founded by Amanda Feilding, Daniel Love, and Rock Feilding-Mellen to construct the operational infrastructure for psychedelic-assisted therapies. Feilding, a half-century force in psychedelic science and policy, established the Beckley Foundation and Beckley Psytech before this entity. Love brought nearly two decades of experience spanning Julian Robertson's family foundation, venture-backed startups, and large corporates. Feilding-Mellen contributed twenty-plus years in politics, policy, and sustainable real estate. Together, they built a holding company rather than a drug developer, signaling a conviction that clinics, training, and care delivery would become the binding constraint as therapies won regulatory approval. The firm builds and operates assets across the care delivery stack. Its portfolio spans clinical services, practitioner training, digital health tools, and policy research. Beckley Waves does not develop pharmaceutical compounds; it acquires, incubates, and scales businesses that will sit between an approved therapy and the patients who need it. The geographic footprint centers on the United Kingdom and the United States, with active monitoring of regulatory pathways in Australia and the European Union. The firm structures deals as direct holdings and strategic partnerships, reflecting a permanent-capital posture rather than a fixed-life venture fund. Named portfolio companies or incubated projects are not publicly cataloged in available materials; the firm's Special Projects Lead runs The Trip Report, a publication tracking industry developments that doubles as a discovery mechanism. Total deployment is not disclosed. Team scale is not publicly broken out beyond the five named professionals on the firm's site. Additional offices outside Oxford have not been confirmed. The firm operates adjacent editorial assets through The Trip Report, a newsletter and analysis platform edited by Zach Haigney. Amanda Feilding's linked entities — the Beckley Foundation for policy research and Beckley Psytech for drug development — orbit Beckley Waves without shared governance, creating an ecosystem that can advocate, invent, and implement across the psychedelic value chain. Beckley Waves' structural difference is its status as a pure-play care delivery holding company in a field dominated by biotech startups chasing FDA approvals. By holding operating businesses rather than managing a fund, the firm aligns with multi-decade regulatory and cultural timelines without redemption pressure. This architecture lets it roll up clinics, training academies, and digital platforms under one roof, a consolidation strategy resembling a healthcare services roll-up more than a venture portfolio. Succession and governance run through the three co-founders, with Amanda Feilding's legacy institutions providing scientific and policy ballast.